History of Tuberculosis

Skeletal changes, lipid biomarkers, and ancient DNA support the presence of tuberculosis in human communities by the Neolithic period, including the eastern Mediterranean. Evidence from pre-contact South America also shows that the disease's deep history cannot be reduced to a simple story of European export. Yet most pulmonary disease leaves no distinctive trace in bone, and lesions can have more than one cause; palaeopathologists therefore grade diagnoses rather than attaching “TB” confidently to every wasted or deformed body. [1]

Greek phthisis and the English “consumption” evoked wasting. “Scrofula” usually meant chronically enlarged neck glands and was also entangled with the European royal-touch tradition. Such diagnoses may include cases now attributed to tuberculosis, but also illnesses that a modern clinician would separate. They record historical observation and explanation, not the uninterrupted recognition of one microbial entity. [2]

In his 1819 treatise on diseases of the chest, the Paris physician René Laennec connected varied clinical and post-mortem findings through the tubercle, arguing that pulmonary phthisis and several apparently different lesions belonged to one pathological process. His synthesis did not identify a microorganism, but it helped make “tuberculosis” a coherent disease category. [4]

In 1865 the French military physician Jean-Antoine Villemin reported that material from human tuberculous lesions produced disease when inoculated into rabbits. His experiments strengthened an infectious interpretation at a time when heredity, constitutional weakness, local inflammation, and contagion remained competing or overlapping explanations. Other investigators then studied transmission and pathological similarity in people and animals. [2]

On 24 March 1882, Robert Koch, working at the Imperial Health Office in Berlin, presented evidence for a specific “tubercle bacillus.” He made the organism visible in diseased tissue with a staining method, cultivated it, and used cultured material to reproduce tuberculosis in experimental animals. His published argument explicitly acknowledged earlier inoculation and inhalation experiments. Koch's paper is a primary source for his methods and causal claims; it is not a record of patient experience, and its language of proof belongs to a laboratory programme that used animals and aimed to establish bacteriology's authority. [3] [4]

In 1890 Koch announced that a culture-derived preparation, soon called tuberculin, might treat tuberculosis. Public expectation and professional demand ran ahead of adequate clinical evidence, while Koch initially withheld its composition. Patients travelled to Berlin, doctors experimented with dosing, and severe reactions exposed the gap between laboratory theory and bedside safety. By early 1891 pathological and clinical reports had undermined the claim that tuberculin cured pulmonary disease. [4]

Tuberculin later became useful in modified form as evidence of an immune response to infection, not as the promised cure. That afterlife should not erase the original failure. The episode shows why Koch's 1882 causal work and his therapeutic claims must be assessed separately, and why later fame is not proof that every contemporary assertion was sound. [4]

The bacillus is necessary to tuberculosis, but infection does not make social conditions incidental. Crowded housing and workplaces increased exposure; undernutrition and other illness affected progression and survival; insecure income made prolonged rest difficult; and fees, distance, and institutional rules shaped access to diagnosis and care. Nursing at home transferred much work and risk to relatives, often women. The literary image of refined, pallid “consumption” in parts of European and North American culture was never a representative account of who carried the burden. [5] [12] [15]

Colonial medicine often converted inequality into racial theory. In South Africa, for example, the political economy of Black labour and racially unequal public-health provision shaped the tuberculosis epidemic; claims of innate “racial susceptibility” diverted attention from work, housing, wages, migration, and services. Similar assumptions influenced policy in East Africa and on Native American reservations. These histories make “population susceptibility” a claim to investigate, not a neutral explanation. [6] [12]

Tuberculosis mortality in England, Wales, the United States, and other industrialized settings began to fall before effective chemotherapy. There is no agreed single cause. Thomas McKeown emphasized improved nutrition and living standards; critics argued that he undervalued housing reform, local public-health services, isolation, and measures against bovine disease. Comparative local studies find different combinations and timings. The safe conclusion is that pre-antibiotic decline was real and multi-causal, not that medicine or social policy can be assigned one universal percentage of credit. [5]

At the Pasteur Institute in Lille, Albert Calmette and Camille Guérin repeatedly cultured a bovine tubercle bacillus from 1908 until it lost virulence in experimental animals. In Paris in 1921, Benjamin Weill-Hallé and Raymond Turpin administered the resulting bacille Calmette–Guérin (BCG) orally to a newborn. This was a collaboration across laboratories, hospitals, veterinary research, and vaccine production—not the work of one inventor. [7]

Confidence was shaken in 1930 when 251 infants in Lübeck received BCG accidentally contaminated with virulent M. tuberculosis; 72 died of tuberculosis. Investigation attributed the deaths to laboratory contamination, not reversion of BCG itself, but the disaster exposed failures of production and oversight. After the Second World War, Scandinavian voluntary agencies, UNICEF, and the World Health Organization supported large campaigns. Countries still adopted different policies because trials produced variable estimates of protection and TB burdens differed. [7]

Present evidence distinguishes strong protection against severe disseminated and meningeal tuberculosis in children from less consistent protection against adult pulmonary disease. That distinction explains why BCG could save lives without becoming a stand-alone route to eradication. [7]

At Rutgers University in 1943, graduate researcher Albert Schatz isolated streptomycin in Selman Waksman's laboratory; Schatz, Elizabeth Bugie, and Waksman reported the substance together in 1944. Naming the team matters because later accounts and honours often compressed a collaborative and contested discovery into Waksman's achievement alone. [8] [11]

Britain's Medical Research Council began a multicentre comparison of streptomycin plus bed rest against bed rest alone in 1947 and published the results in 1948. Allocation based on random-number schedules was concealed; radiographs were assessed without knowledge of treatment. The design became a landmark in the history of clinical trials, although it was not the first controlled or randomized therapeutic experiment. Nor did it meet present consent standards: patients were not told that they were taking part in a special comparative study. Postwar scarcity of imported streptomycin shaped both access and the trial's ethical setting. [9] [11]

Streptomycin produced substantial short-term improvement, but monotherapy rapidly selected resistant bacilli. A second MRC report in 1950 showed that combining streptomycin with para-aminosalicylic acid (PAS) greatly reduced streptomycin resistance. Isoniazid, introduced in 1952, strengthened multidrug regimens; rifampicin later helped shorten them. Combination therapy—not a single “magic bullet”—made durable cure more reliable and moved many patients from prolonged institutional care toward outpatient treatment. [9] [10]

Antibiotics closed many sanatoria in wealthier countries, but global control depended on diagnosis, reliable drug supply, trained staff, follow-up, and regimens patients could complete while sustaining work and family life. Programmes that treated a technical prescription as sufficient often ignored those material conditions. Resistance could be selected by inadequate or interrupted therapy and then transmitted to people who had never received the affected drugs; it should not be reduced to a story of individual “non-compliance.” [12] [13]

From the 1980s, HIV made progression from infection to active tuberculosis much more likely and exposed the damage caused by weakened services and therapeutic complacency. The resurgence, especially in sub-Saharan Africa, joined two programmes that had often been organized separately. It also demonstrated why a decline in Europe or North America could not stand for a universal end to tuberculosis. [12] [13]

In current medical usage, TB infection is not the same as TB disease: most infected people have no symptoms and are not contagious, while active disease can affect the lungs or other organs and requires treatment. This brief distinction helps interpret the past; it is not diagnostic advice. Historical categories such as “latent tuberculosis” changed with tuberculin testing, radiography, microbiology, and screening policy, so they should not be assumed to mean exactly what present guidelines mean. [13]